Cencora (COR) is a Top-Ranked Value Stock: Should You Buy?

Core Insights - Zacks Premium offers tools for investors to enhance their stock market strategies and confidence, including daily updates, research reports, and stock screens [1] - The Zacks Style Scores are designed to complement the Zacks Rank, providing ratings based on value, growth, and momentum methodologies to help investors identify stocks likely to outperform the market [2] Zacks Style Scores Overview - Each stock is rated from A to F based on value, growth, and momentum, with A being the highest score indicating a better chance of outperforming [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, each focusing on different investment strategies [3][4][5][6] Value Score - The Value Score identifies attractive and discounted stocks using various financial ratios such as P/E, PEG, and Price/Sales, appealing to value investors [3] Growth Score - The Growth Score emphasizes a company's financial health and future outlook, analyzing projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [4] Momentum Score - The Momentum Score helps investors capitalize on price trends by analyzing short-term price changes and earnings estimate revisions [5] VGM Score - The VGM Score combines the three Style Scores to identify stocks with the best value, growth potential, and momentum, serving as a strong indicator alongside the Zacks Rank [6] Zacks Rank and Style Scores Interaction - The Zacks Rank utilizes earnings estimate revisions to guide investors in building successful portfolios, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] Company Spotlight: Cencora - Cencora, based in Chesterbrook, PA, is a leading pharmaceutical services company focused on drug distribution and healthcare cost reduction [11] - Cencora holds a Zacks Rank of 2 (Buy) and a VGM Score of A, with a Value Style Score of A due to a forward P/E ratio of 17.67, making it attractive for value investors [11] - Recent analyst revisions have increased Cencora's earnings estimate for fiscal 2025 by $0.27 to$15.36 per share, with an average earnings surprise of 4.9% [12]